Skip to main content

Table 1 Liver function tests for the groups treated with or without CCl4 or MSC-Smad7 for 21 days

From: Mesenchymal stem cell-based Smad7 gene therapy for experimental liver cirrhosis

Group Number ALT(U/L) AST(U/L) ALB (g/dl) TP (g/dl)
Control 6 26.8 ± 9.2 66.9 ± 7.8 43.7 ± 9.1 70.7 ± 7.4
CCl4-treated 6 128.6 ± 10.3*** 138.4 + 6.1*** 23.4 ± 8.6** 43.8 + 6.4***
CCl4+MSC 6 119.6 ± 10.1*** 135.7 ± 6.8*** 22.8 ± 8.1** 44.9 ± 6.3***
CCl4+MSC-Smad7 6 65.3 ± 11.9*, ### 82.9 ± 7.7**,### 31.7 ± 7.1* 63.6 ± 5.3###
  1. ALT alanine transaminase, AST aspartate transaminase, ALB albumin, TP total protein. *P < 0.05, **P < 0.01 and ***P < 0.001 comparing with the control group. #P < 0.05, ##P < 0.01 and ###P < 0.001 comparing with the CCl4-treated group